Where will leukemia research go next?
The future of CLL treatment
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
CLL2-GIVe trial: investigating chemotherapy-free treatment of CLL
ASCO 2016 highlights for CLL